Dr. Raymond J. Tesi, MD ,is the Co-founder of INmuneBio Inc. and has been its Chief Executive Officer, President and Director since September 2015. Dr. Tesi served as President and Chief Executive Officer of Fortress Biotech, Inc. (formerly, Coronado Biosciences, Inc.). Dr. Tesi served as Executive Vice President of Clinical Development & Medical Affairs at Cellerant Therapeutics, Inc. Dr. Tesi served as Senior Vice President of Clinical Development & Medical Affairs at SangStat Medical Corporation. He joined SangStat in May 1997. In this position, he supported Thymoglobulin, an immunosuppressive antibody used in transplantation and lead the clinical development of RDP58, a novel therapeutic peptide in development for autoimmunity. Prior to SangStat, Dr. Tesi served as an associate professor of surgery and director of the extra-renal transplantation program at Tulane Medical School in New Orleans, LA. He received his transplantation surgical fellowship training at the Ohio State University Hospital, where he was on the staff for 5 years and has been active clinically in kidney, pancreas, liver and small bowel transplantation. Dr. Tesi has authored or presented 139 journal articles and abstracts in many areas of solid organ transplantation. He received his M.D. from the Washington University School of Medicine in St. Louis, MO.